CA-CEPTON-TECHNOLOGIES
9.9.2019 15:02:04 CEST | Business Wire | Press release
CNL Software, a world leader in Physical Security Information Management (PSIM) software, is pleased to announce a technology partnership with Cepton Technologies, a developer of industry-leading 3D sensing solutions, at the GSX in Chicago. The partnership will drive the automation of threat detection, tracking and escalation in real time using the latest PSIM, LiDAR and video assessment technologies.
Cepton Technologies’ Helius™ system is a smart lidar network utilizing edge computing to provide real-time detection, tracking and classification. It can seamlessly track an object from sensor to sensor, providing 3D data on location, dimensions, and velocity, while maintaining the same identification of the object.
By connecting multiple laser-powered sensors, it offers comprehensive coverage of a given area as well as high resolution imaging of objects. Sensors can be clustered as needed but act as one to maximize the simplicity of use and integration. With the in-built software in the hardware unit, Helius is browser-based and can launch on computers and mobile devices for instant monitoring and configuration, without installations of additional software. Furthermore, being edge-based, Helius processes data locally and outputs low-bandwidth data to the central server.
“CNL Software is committed to working with new and innovative technologies that will give our customers improved security and greater efficiency. Cepton’s lidar sensor technology brings the technological leaps that have taken place in autonomous vehicles to the security industry, especially in the government and critical infrastructure markets where we are experiencing growing demand for the integration of multiple different security system and sensor technologies,” comments Keith Bloodworth, CEO, CNL Software. “When integrated with IPSecurityCenterTM , Helius further enhances the industry’s most comprehensive PSIM system solution, providing users with access to more of the tools they need to quickly see, understand, assess and properly resolve perimeter security and surveillance incidents, consistently.”
Neil Huntingdon, Cepton’s VP of Business Development, added: “Our technology’s ability to detect and track events in traditionally difficult environments combined with IPSecurityCenter’s ability to correlate this data with data from other security systems and sensors and provide decision support is a powerful proposition. We’re really excited to be partnering with CNL Software to bring this game changing solution to the government, critical infrastructure, safe city and transportation markets, in particular. It will unlock that ‘missing layer’ by filling the medium-range sensor gap and improve it with the capability to classify objects as well as behaviors.”
For more information about CNL Software’s PSIM solution and deployments, please visit Booth #1713 at the GSX in Chicago on September 10– 12 2019. To book a demonstration, please email marketing@cnlsoftware.com
About Cepton Technologies, Inc.
Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.
Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.
Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines. For more information, visit: http://www.cepton.com/ .
Cepton will also have a separate booth at stand 1894, next to the bistro.
About CNL Software
More than a decade ago, we set out to create a PSIM platform to transform the way organizations manage their physical security. Today, IPSecurityCenter is trusted by the best-informed security operations in national security, critical infrastructure and large enterprises around the world. For more information, visit www.cnlsoftware.com .
Physical Security Information Management (PSIM) LinkedIn Group
The PSIM Group brings together users, integrators, consultants and manufacturers of Physical Security Information Management software to share ideas, thought leadership, tips, tricks, future developments and more! Please follow visit https://www.linkedin.com/groups/2162880
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom